1 Title: Evaluation of immunological responses to third COVID-19 vaccine among people 2 treated with sphingosine receptor-1 modulators and anti-CD20 therapy

3

Authors: Ilana Katz Sand MD,<sup>1</sup> Sacha Gnjatic PhD<sup>2,3,4</sup>, Florian Krammer PhD<sup>4,5</sup>, Kevin
Tuballes<sup>2</sup>, Juan Manuel Carreño<sup>5</sup>, Sammita Satyanarayan MD,<sup>1</sup> Susan Filomena BA,<sup>1</sup>
Erin Staker BS,<sup>1</sup> Johnstone Tcheou<sup>5</sup>, Aaron Miller MD,<sup>1</sup> Michelle Fabian MD,<sup>1</sup> Neha Safi
MD,<sup>1</sup> Jamie Nichols MD,<sup>1</sup> Jasmin Patel MD,<sup>1</sup> Stephen Krieger MD,<sup>1</sup> Stephanie Tankou
MD, PhD,<sup>1</sup> Sam Horng MD, PhD,<sup>1</sup> Sylvia Klineova MD,<sup>1</sup> Erin Beck MD, PhD,<sup>1</sup> Miriam
Merad MD, PhD,<sup>2,3</sup> Fred Lublin MD<sup>1</sup>

10

Affiliations: 1. Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of
Neurology, Icahn School of Medicine at Mount Sinai, 2. Precision Immunology Institute,
Human Immune Monitoring Center, 3. Department of Oncological Sciences, Icahn School
of Medicine at Mount Sinai, New York, NY 10029, 4. Department of Pathology, Icahn
School of Medicine at Mount Sinai, New York, NY 10029. 5. Department of Microbiology,
Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine
Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount

- 18 Sinai, New York, NY, USA,
- 19

# 20 **Corresponding Author**:

- 21 Ilana Katz Sand, MD
- 22 Corinne Goldsmith Dickinson Center for Multiple Sclerosis
- 23 5 E. 98<sup>th</sup> Street
- 24 Suite 1138
- 25 New York, NY 10029
- 26 ilana.katzsand@mssm.edu
- 27 212-241-6854
- 28
- 29
- 30

# 31 Abstract

32

Importance: People living with multiple sclerosis (MS) and other disorders treated with immunomodulatory therapies remain concerned about suboptimal responses to coronavirus disease 2019 (COVID-19) vaccines. Important questions persist regarding immunological response to third vaccines, particularly with respect to newer virus variants.

- 38 **Objective:** Evaluate humoral and cellular immune responses to third COVID-19 vaccine
- 39 dose in people on anti-CD20 therapy and sphingosine 1-phosphate receptor (S1PR)
- 40 modulators, including Omicron-specific assays.
- 41 **Design:** Observational study evaluating immunological response to third COVID-19 42 vaccine dose in volunteers treated with anti-CD20 agents, S1PR modulators, and healthy
- 43 controls. Neutralizing antibodies against USA-WA1/2020 (WA1) and B.1.1.529 (BA.1)
- 44 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were measured before
- 45 and after third vaccine. Cellular responses to spike peptide pools generated from WA1
- 46 and BA.1 were evaluated.
- 47 **Setting:** Mount Sinai Hospital
- 48 Participants: People treated with anti-CD20 therapy or S1PR modulators and healthy
   49 volunteers
- 50 **Exposure:** Treatment with anti-CD20 therapy, S1PR modulator, or neither
- 51 **Main outcomes and measures:** Serum neutralizing antibodies and *ex vivo* T cell 52 responses against SARS-CoV-2 antigens.
- Results: This cohort includes 25 participants on anti-CD20 therapy, 12 on S1PR 53 54 modulators, and 14 healthy controls. Among those on anti-CD20 therapy, neutralizing antibodies to WA1 were significantly reduced compared to healthy controls (ID50% GM 55 56 post-vaccination of 8.1 ± 2.8 in anti-CD20 therapy group vs 452.6 ± 8.442 healthy 57 controls, P<0.0001) and neutralizing antibodies to BA.1 were below the threshold of 58 detection nearly universally. However, cellular responses, including to Omicron-specific 59 peptides, were not significantly different from controls. Among those on S1PR 60 modulators, neutralizing antibodies to WA1 were detected in a minority, and only 3/12had neutralizing antibodies just at the limit of detection to BA.1. Cellular responses to 61 Spike antigen in those on S1PR modulators were reduced by a factor of 100 compared 62
- to controls (median 0.0008% vs. 0.08%, p<0.001) and were not significantly "boosted" by
- 64 a third injection.
- 65 **Conclusions and Relevance:** Participants on immunomodulators had impaired antibody 66 neutralization capacity, particularly to BA.1, even after a third vaccine. T cell responses 67 were not affected by anti-CD20 therapies, but were nearly abrogated by S1PR 68 modulators. These results have clinical implications warranting further study.
- 69 70
- 70

# 71 Manuscript Text

# 72 Introduction

Many people receiving treatment with immunomodulatory therapies, including those living
 with multiple sclerosis (MS), remain apprehensive about COVID-19 risk.

75 Among common therapies for MS, there is high concern with anti-CD20 agents and sphingosine 1-phosphate receptor (S1PR) modulators. Anti-CD20 agents deplete 76 77 circulating B cells and, to a lesser extent, subsets of CD4 and CD8 cells expressing low 78 levels of CD20.<sup>1</sup> In addition to widespread use in MS, anti-CD20 agents are utilized to 79 treat B cell malignancies and a range of immune-mediated neurological and 80 rheumatologic disorders.<sup>2</sup> S1PR modulators functionally block S1PR function, sequestering lymphocytes in the lymph nodes and thymus.<sup>3</sup> In addition to use in MS, the 81 S1PR modulator ozanimod was recently approved for ulcerative colitis and ponesimod is 82 83 currently in late stage clinical trials for psoriasis and graft-vs.-host disease.

84

Previous data suggest reduced humoral response to the primary vaccine series related to these treatments<sup>4-6</sup>. Limited evidence suggests preserved cellular response to vaccination with anti-CD20 therapies and reduced response with S1PR modulators.<sup>7, 8</sup> Epidemiologic studies have suggested worse clinical outcomes with these therapies.<sup>9</sup>

89

Here we address the most recent significant questions regarding the production of neutralizing antibodies and cellular immune responses before and after third COVID-19 vaccinations in people treated with these immunomodulatory therapies, importantly accounting for the recent Omicron variant.

# 9495 Methods

96 Sample

All participants were recruited between Mount Sinai's MS Center and Human Immune Monitoring Center. Eligible participants began treatment with B cell or S1P modulator therapy at least 60 days prior to third vaccine or were healthy volunteers. For this analysis, we included all enrollees who had completed baseline sampling prior to a third injection and a follow-up sample approximately 4 weeks after the third vaccination by early January 2022.

- 103
- 104 Assessing Humoral and Cellular Immunity

Microneutralization assays against USA-WA1/2020 (WA1, or wild-type) and B.1.1.529 105 106 (BA.1, or Omicron variant) SARS-CoV-2 were performed at the Icahn School of Medicine as previously described.<sup>10</sup> Groups were compared by one-way ANOVA with Tukey 107 108 multiple comparisons. T cell responses were assessed by IFN-gamma ELISPOT using 109 400,000 peripheral blood mononuclear cells pulsed with various antigens (15-mer 110 overlapping peptide pool covering the entire sequence of Spike antigen (both WT and 111 Omicron variants, from Miltenyi Biotec), N & Orf antigens (Bhardwaj, GenScript), long peptides covering the Spike RBD domain (Biosynthesis), recombinant Spike protein (gift 112 113 from Drs. Herrera and Garforth, Einstein College of Medicine), and control viral peptide 114 pools, DMSO, and PMA+ionomycine, as described.<sup>11</sup> Responses were considered 115 positive if >20 spots were detected and at least 2x more than the number of spots to

116 DMSO. Pre-post comparisons were made by Wilcoxon paired t-tests, inter-cohort 117 comparisons by Mann-Whitney t-test.

118

#### 119 **Results**

120 **Table 1** describes 25 participants on B cell therapy, 12 on S1PR modulators, and 14 121 controls.

122

123 Figure 1 illustrates neutralizing antibody titers. Few on B-cell therapies mounted 124 detectable neutralizing antibodies to WA1 (n=4, 2 just above the limit of detection (LoD)), 125 with some increasing after the third vaccination (n=7, 4 just above the LoD). None had 126 detectable neutralizing antibodies to BA.1 before the third vaccination, and only one 127 converted after third vaccination. Among patients on S1PR modulators, three participants 128 had neutralizing antibodies to BA.1 just at the level of detection post third injection. This contrasts with healthy controls, where a third vaccination resulted in detectable 129 neutralizing antibodies to WA1 (ID50% GM of 59.25 ± 6.536 pre- vs 452.6 ± 8.442 post-130 131 vaccination, P<0.01) and BA.1 (ID50% GM of 6.13 ± 1.418 pre- vs 75.71 ± 3.405 post-132 vaccination, P<0.0001) nearly universally.

133

134 Figure 2 demonstrates the cellular response to spike peptide pools generated from WA1 135 (A) and BA.1 (B) SARS-CoV-2. Although there was more variability among those on B 136 cell therapies compared to controls, overall T cell responses were not significantly 137 different between B cell participants and controls. B cell participants showed significantly 138 increased responses to WA1 and BA.1 peptides after a third injection (median 0.04%) 139 increase, p=0.008 by Wilcoxon paired test). Responses to WT Spike peptide pool were 140 significantly greater in controls and B cell participants compared to S1PR participants 141 (median 300-450 spots vs. 3 spots out of 400,000 PBMC, p<0.0001). Among S1PR 142 participants, responses were not significantly different before and after third injection 143 (median 0.004% increase). These results were confirmed with the Omicron peptide pool. 144 RBD peptide pool, and Spike full-length protein, though these were generally less reactive 145 in controls as well. Responses to the peptide pool generated from nucleocapsid (N) and 146 open reading frame (ORF) proteins, which reflect naturally occurring immunity rather than 147 vaccine-induced immunity, were not significantly different in MS participants compared to 148 controls. Interestingly, responses to CEFT (cytomegalovirus, Epstein-Barr virus, influenza 149 A virus, *Clostridium tetani*) peptide pools were significantly lower in B cell participants' 150 responses compared to controls.

151

# 152 **Discussion**

153 Participants on both therapies demonstrated significantly reduced production of 154 neutralizing antibodies, particularly to BA.1, as compared to controls. Cellular immune 155 responses to vaccination were similar among those on B cell therapies to controls and increased after a third vaccination. However, S1P participants demonstrated less robust 156 cellular responses. Driving the lack of significant increase among S1P participants is that 157 158 there were very few "converts" after the third vaccination. The cellular response 159 increased with a third vaccination among those who had a measurable response to their 160 first two injections, but did not increase for patients who never responded to the first two

injections. This observation has significant consequences for expected responses toadditional vaccines among those on S1PR modulators.

163

164 Timing of therapy initiation may play a role in vaccine response. The lone B cell participant 165 with a high level of neutralizing antibodies to BA.1 after the third vaccination received the first vaccinations prior to starting therapy, though notably two others who started therapy 166 after the first vaccinations did not develop neutralizing antibodies to BA.1 after the third 167 168 vaccine. Of three S1P participants with neutralizing antibodies to BA.1 just at LOD, two 169 received their first injections prior to starting therapy. These are important preliminary 170 observations that will be relevant to those with new diagnoses or needing to change 171 therapy going forward.

172

Strengths of our study include the presence of a control group and the study of S1PR modulators in addition to B cell therapy. We have assessed the levels of neutralizing antibodies, which reflect the effectiveness of the humoral immune response and represent a mechanistic correlate of protection against SARS-CoV-2,<sup>12, 13</sup> and measured cellular immunity. We have also studied Omicron-specific assays, which more accurately reflect the current circulating strains.

179

Our study is limited by its small size. The cohort includes only one participant over age 65 because of the timing of enrollment (many of those over 65 had already received a third vaccine when enrollment began). We did not quantify the relative contribution of CD8 vs. CD4 T cell responses, though target antigen formulations used in our assays suggest that the third dose is better at increasing CD8 than CD4 T cells.<sup>14</sup> Study design did not permit correlation to clinical outcomes.

186

Future directions include assessing durability of vaccine responses over time, studying the impact of natural infection with new variants, and most importantly, correlation with clinical outcomes. For those on S1PR modulators, future studies could consider brief cessation of therapy to aim for an improved response to additional injection, weighing potential benefits and risks of such a strategy.

- 192
- 193
- 194

Acknowledgments: The authors would like to thank the Fishman family for generously
 supporting this work, as well our patients at the CGD MS Center who graciously donated
 their time and samples to participate in this study.

198

199 SG was partially supported by NIH grants and contracts CA224319, DK124165, 75N91020R00055, CA263705, and CA196521.

201

202 Work in the Krammer laboratory was partially funded by the NIAID Collaborative Influenza 203 Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, the Centers of 204 Excellence for Influenza Research and Surveillance (CEIRS. contract # 205 HHSN272201400008C) and the Serological Sciences Network (SeroNet) in part with 206 Federal funds from the National Cancer Institute, National Institutes of Health, under

207 Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this 208 publication does not necessarily reflect the views or policies of the Department of Health 209 and Human Services, nor does mention of trade names, commercial products or 210 organizations imply endorsement by the U.S. Government.

211

### 212 **Disclosures:**

- 213 SG reports past consultancy or advisory roles for Merck and OncoMed; research funding
- from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, EMD Serono,
- 215 Pfizer, Regeneron Pharmaceuticals, and Takeda, all unrelated to the current work.
- 216

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.

# 225 **References**

Bar-Or A, O'Brien SM, Sweeney ML, Fox EJ, Cohen JA. Clinical Perspectives on the Molecular and
 Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. *CNS Drugs*. Sep
 2021;35(9):985-997. doi:10.1007/s40263-021-00843-8

- 229 2. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances
  230 and mechanistic insights. *Nat Rev Drug Discov*. Mar 2021;20(3):179-199. doi:10.1038/s41573-020-
- 231 00092-2

2323.McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and233other conditions. Lancet. Sep 25 2021;398(10306):1184-1194. doi:10.1016/s0140-6736(21)00244-0

- Satyanarayan S, Safi N, Sorets T, et al. Differential antibody response to COVID-19 vaccines
   across immunomodulatory therapies for multiple sclerosis. *Multiple Sclerosis and Related Disorders*.
   doi:10.1016/j.msard.2022.103737
- 2375.Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 Vaccine Response in People with238Multiple Sclerosis. Ann Neurol. Jan 2022;91(1):89-100. doi:10.1002/ana.26251
- Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients
   treated with disease modifying therapies. *EBioMedicine*. Oct 2021;72:103581.
- 241 doi:10.1016/j.ebiom.2021.103581
- 242 7. Gadani SP, Reyes-Mantilla M, Jank L, et al. Discordant humoral and T cell immune responses to 243 SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. *EBioMedicine*. Nov
- 244 2021;73:103636. doi:10.1016/j.ebiom.2021.103636
- Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following
  SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med*. Nov
  2021;27(11):1990-2001. doi:10.1038/s41591-021-01507-2
- Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 Severity in Multiple Sclerosis: Putting
   Data Into Context. *Neurol Neuroimmunol Neuroinflamm*. Jan
- 250 2022;9(1)doi:10.1212/nxi.00000000001105
- 10. Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against
- 252 SARS-CoV-2 Omicron. *Nature*. 2022/02/01 2022;602(7898):682-688. doi:10.1038/s41586-022-04399-5

253 11. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self-

antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
 *Clin Cancer Res.* Dec 1 2012;18(23):6497-508. doi:10.1158/1078-0432.Ccr-12-2189

256 12. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of

257 immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine*. 2021/07/01

258 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8

259 13. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273

260 COVID-19 vaccine efficacy clinical trial. *Science*. 2022;375(6576):43-50.

261 doi:doi:10.1126/science.abm3425

262 14. Gnjatic S, Atanackovic D, Matsuo M, et al. Cross-presentation of HLA class I epitopes from

exogenous NY-ESO-1 polypeptides by nonprofessional APCs. *J Immunol*. Feb 1 2003;170(3):1191-6.

264 doi:10.4049/jimmunol.170.3.1191

265

266

Table 1 - (	Clinical Characteristics (n=51)			
		Control (n=14)	S1P (n=12)	Bcell (n=25)
	Age (years), median (range)	31 (24-61)	42 (31-69)	49 (26-65)
	Sex	0 (649()	7 (500()	42 (400()
	Male, n (% total)	9 (64%)	7 (58%)	12 (48%)
	Race	5 (50%)	5 (42%)	13 (52%)
	White, n (% total)	12 (85%)	11(92%)	22 (88%)
	Black, n (% total)	0(0%)	1 (8%)	0 (0%)
	Asian, n (% total)	1 (7%)	0 (0%)	2 (8%)
	Biracial, n (% total)	1 (7%)	0 (0%)	1 (4%)
	Hispanic n (% total)	2 (1/%)	1 (8%)	2 (8%)
	Non-Hispanic, n (% total)	12 (86%)	11(92%)	2 (8%)
	Disease Category	12 (0070)	11(3270)	25 (5270)
	none, n (% total)	13(93%)	0 (0%)	0 (0%)
	RRMS, n (% total)	1 (7%)	11 (92%)	21 (84%)
	SPMS, n (% total)	0 (0%)	1 (8%)	1 (4%)
	PPMS, n (% total)	0 (0%)	0 (0%)	2 (8%)
	MOG, n (% total)	0 (0%)	0 (0%)	1 (4%)
	Disease Modifying Therapy (DMT)			
	none. n (% total)	13(93%)	0 (0%)	0 (0%)
	teriflunomide.n (% total)	1 (7%)	0 (0%)	0 (0%)
	S1P Class			
	fingolimod, n (% total)	0 (0%)	8 (67%)	0 (0%)
	siponimod, n (% total)	0 (0%)	2 (17%)	0 (0%)
	ozanimod, n (% total)	0 (0%)	2 (17%)	0 (0%)
	Anti-CD20 Class	0 (00()	0 (00()	2 (00()
	ntuximab, n (% total)	0 (0%)	0 (0%)	2 (8%)
	ofatumumab, n (% total)	0 (0%)	0 (0%)	1 (4%)
		0 (070)	0 (070)	1 (470)
	DMT duration (days), median (range)	n/a*	1471 (69-3888)	1185 (112-2629)
	Vaccine Type			
	Pfizer, n (% total)	11(79%)	5 (42%)	13 (52%)
	Moderna, n (% total)	3 (21%)	5 (42%)	12 (48%)
	J&J, n (% total)	0 (0%)	2 (16%)	0 (0%)
	days(median_range)	279 (2/12-317)	183 (1/17-257)	207 (48-287)
	Immunological Testing	275 (242-517)	105 (147-257)	207 (40-207)
	T0 (pre-booster), days- (median, range)	0 (0-7)	5 (0-21)	3 (0-21)
	T4 (4 weeks post boooster)- days (median, range)	28 (26-45)	28 (23-37)	29 (22-39)
	Covid-19 Infection History***			
	None, n (% total)	11 (79%)	12 (100%)	19 (76%)
	Suspected, n (% total)	2 (14%)	0 (0%)	3 (12%)
	Confirmed, n (% total)	1 (7%)	0%	3 (12%)
	*DMT duration defined as time from DMT start to			
	booster date for all patients. Of note, 1 control			
	patient was on Aubagio (active comparator) and time			
	from dmt start for that patient was 2694 days.			
	** Vaccine interval is defined by the time between			
	the 2nd vaccination and 3rd vaccination for patients			
	receiving Prizer or Moderna vaccines, and is defined			
	for patients receiving 1&1			
	***Covid-19 Infection was defined as suspected or			
	confirmed covid-19 prior to 3rd vaccination (or 2nd	8		
	vaccination for patients with J&J). Controls (n=3), S1P	-		
	(n=0), Anti-CD20 (n=6).			

Figure 1. Neutralizing antibodies. Neutralization expressed as the inhibitory dilution 50% ( $ID_{50}$ ) of sera against USA-WA1/2020 (WT, shown in A) and B.1.1.529 (Omicron, shown in B) SARS-CoV-2 live viruses in the three groups: B cell, S1P, and healthy controls. Group comparisons performed using a One-way ANOVA with Tukey multiple comparisons; ns: not significant, \* p<0.05, \*\* p<0.01, \*\*\*\* p<0.001, \*\*\*\* p<0.001

272 comp 273

Figure 1



274 275

- 275
- 277
- 278
- 279
- 280

281 Figure 2. Cellular response. Number of positive interferon (IFN)- v spots (log scale) out 282 of 400,000 PBMC for the three groups: B cell, S1P, and healthy controls against the indicated antigens: Spike WT peptide pool WA1 (A); Spike omicron variant peptide pool 283 284 (B); Spike full-length protein (C); long peptide pool covering Spike RBD domain (D); 285 positive control viral peptide pool CEFT [from CMV, EBV, influenza, and tetanus] (E); SARS-CoV-2 N & Orf peptide pool (F); and assay control PMA/Ionomycin, out of 40,000 286 PBMCs (G). Intergroup comparisons by Mann-Whitney t-test in bold, pre-post 287 288 comparisons by Wilcoxon paired test; ns: not significant, \*: p<0.05, \*\* p<0.01, \*\*\* p<0.001, 289 \*\*\*\* p<0.0001.















291

292